Malignant glioma: Who benefits from adjuvant chemotherapy?

Lisa M. DeAngelis; Peter C. Burger; Sylvan B. Green; J. Gregory Cairncross

doi:10.1002/ana.410440418

Malignant glioma: Who benefits from adjuvant chemotherapy?

Lisa M. DeAngelis
, Peter C. Burger
, Sylvan B. Green
, J. Gregory Cairncross

School of Medicine

Research output: Contribution to journal › Article › peer-review

125 Scopus citations

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

Original language	English (US)
Pages (from-to)	691-695
Number of pages	5
Journal	Annals of neurology
Volume	44
Issue number	4
DOIs	https://doi.org/10.1002/ana.410440418
State	Published - Oct 1998

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.410440418

Cite this

@article{6fb08c5cf6f14b2fb2d428036f81b58d,

title = "Malignant glioma: Who benefits from adjuvant chemotherapy?",

abstract = "We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.",

author = "DeAngelis, \{Lisa M.\} and Burger, \{Peter C.\} and Green, \{Sylvan B.\} and Cairncross, \{J. Gregory\}",

year = "1998",

month = oct,

doi = "10.1002/ana.410440418",

language = "English (US)",

volume = "44",

pages = "691--695",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley \& Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Malignant glioma

T2 - Who benefits from adjuvant chemotherapy?

AU - DeAngelis, Lisa M.

AU - Burger, Peter C.

AU - Green, Sylvan B.

AU - Cairncross, J. Gregory

PY - 1998/10

Y1 - 1998/10

N2 - We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

AB - We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

UR - https://www.scopus.com/pages/publications/0031755577

UR - https://www.scopus.com/pages/publications/0031755577#tab=citedBy

U2 - 10.1002/ana.410440418

DO - 10.1002/ana.410440418

M3 - Article

C2 - 9778271

AN - SCOPUS:0031755577

SN - 0364-5134

VL - 44

SP - 691

EP - 695

JO - Annals of neurology

JF - Annals of neurology

IS - 4

ER -

Malignant glioma: Who benefits from adjuvant chemotherapy?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this